Results 211 to 220 of about 97,023 (309)

Emergency Department Opt‐Out Testing for Hepatitis B: A Two‐Year UK Multicentre Evaluation of Outcomes Across Seven Sites

open access: yesLiver International, Volume 46, Issue 6, June 2026.
ABSTRACT Background and Aims An estimated 270 000 people in the UK live with hepatitis B infection, the leading global cause of liver cancer. In 2022, opt‐out hepatitis B testing was introduced in emergency departments (ED) in London. We conducted a 2‐year multicentre evaluation of this programme across seven sites.
Jennifer J. Plunkett   +15 more
wiley   +1 more source

When Hepatitis B Virus-Associated Glomerulonephritis Mimics Lupus Nephritis: A Case of Adult-Onset Disease With Full-House Pattern. [PDF]

open access: yesKidney Med
Kono K   +15 more
europepmc   +1 more source

Detection of Diagnostic Antibodies in Immune‐Mediated Diseases: A Focus on Antigens and Technologies

open access: yesChemBioChem, Volume 27, Issue 9, 14 May 2026.
This review explores autoantibody detection in immune‐mediated diseases, highlighting autoantigens including post‐translational modifications. We compared enzyme‐linked immunosorbent assay and indirect immunofluorescence with automated chemiluminescence platforms.
Silvia Bracci   +5 more
wiley   +1 more source

Safe and Localized Lentiviral Gene Delivery via Injectable Mesoporous Scaffolds for Potent Antitumor Immunity

open access: yesAdvanced Materials, Volume 38, Issue 25, 4 May 2026.
This work introduces an injectable mesoporous silica rod scaffold that confines lentiviral vectors to the injection site, enabling localized dendritic cell recruitment and transduction. The platform sustains antigen expression, promotes robust T‐cell activation, and enhances antitumor immunity.
Thanh Loc Nguyen   +12 more
wiley   +1 more source

Immune Checkpoint Inhibitors and Immunomodulators for Cancer Immunotherapy: Insights Into Resistance and Therapeutic Strategies

open access: yesAdvanced Science, Volume 13, Issue 25, 4 May 2026.
The schematic diagram illustrates the roles of novel immune checkpoints, immunomodulatory factors, cell death and multimodal technologies in cancer immunotherapy. Abstract Cancer immunotherapy has redefined cancer treatment. However, the molecular and cellular basis of immune evasion and therapeutic resistance remains incompletely understood.
Fangquan Chen   +7 more
wiley   +1 more source

Overcoming Immunotolerance in Chronic Hepatitis B: Efficacy of Granulocyte-Macrophage Colony-Stimulating Factor-Based Immunotherapy in Achieving Hepatitis B Surface Antigen Seroclearance. [PDF]

open access: yesMedComm (2020)
Geng S   +16 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy